Nasdaq GlobeNewswire

Nasdaq BWise GRC Platform selected by State General Reserve Fund for Enterprise Risk Management

Del

MUSCAT, Oman and NEW YORK, 2016-04-19 10:00 CEST (GLOBE NEWSWIRE) --

Nasdaq BWise (Nasdaq:NDAQ), a global leader in enterprise Governance, Risk Management and Compliance (GRC), announced today that it has been selected by State General Reserve Fund (SGRF), the largest sovereign wealth fund in the Sultanate of Oman, to support their enterprise risk management (ERM) processes based on the principles of the COSO ERM methodology. 

SGRF was looking for a software solution to enhance its risk and control management practices based on the COSO ERM principles that could be embedded across the organization providing one, holistic view on the companies’ risks. The BWise Rapid Deployment approach (RDS) for Enterprise Risk Management will support SGRF in standardizing their risk management practices across the organization, provide one source of integrated information, enable better risks and controls analysis, and streamline overall risk management.

“We were searching for a risk tool that was able to deliver on most of the COSO ERM components, but we wanted to keep things simple, easy to use and fast to process,” said Susan Daniel, Director of Risk and Compliance, SGRF. “BWise was selected because of the rich functionality of its enterprise risk management solution and best practices based implementation plan from the BWise team.”

State General Reserve Fund (SGRF) was established in 1980 by a Royal Decree 1/80. It endeavors to achieve long term sustainable returns on the revenues generated from the oil and gas, and that are surplus to the state's budgetary requirements. On behalf of the Government of Oman, SGRF manages the reserves placed in its care to achieve best possible long term returns with acceptable risks, through investing in a diversified portfolio of asset classes in more than 25 countries worldwide.

“We are proud to be working with the State General Reserve Fund, which is one of the world’s leading sovereign wealth funds,” said Rob van Straten, Global Head of Sales and Professional Services, Nasdaq BWise. “We have been delivering successful projects in the Gulf States for several years, with demand increasing in the industrial sector as well as from financial services companies and institutions. Our best practice-based delivery is often selected to ensure short implementation times. Additionally, customers can deploy BWise easily across their organizations as BWise supports the Arabic language.” 

The BWise Rapid Deployment delivery method for Enterprise Risk Management offers a standard approach that provides practical steps and logical procedures to build a consistent ERM Program. The BWise RDS ERM includes pre-defined fields, data and authorization models, processes, workflows and sets of reports based on best practices and ERM standards to get an organization started with solid risk management GRC practices quickly.

About Nasdaq BWise
Nasdaq BWise is a global leader in Enterprise Governance, Risk Management and Compliance (GRC) software. Based on a strong heritage in business process management, the BWise® GRC Platform provides companies with highly-rated, proven software solutions for Risk Management, Internal Control, Internal Audit, Compliance & Policy Management, Information Security and Sustainability Performance Management.

BWise’s end-to-end solutions support an organization’s ability to understand, track, measure, and manage key organizational risks. Nasdaq BWise helps companies truly be in control by balancing performance with their financial and reputational risks, improving corporate accountability, increasing financial, strategic and operating efficiencies. Using BWise, organizations are able to efficiently comply with anti-corruption regulations like FCPA and the UK Bribery Act, the Sarbanes-Oxley Act, European Corporate Governance Codes, ISAE3402/SAS-70, PCI-DSS, Solvency II, Basel II and III, Dodd-Frank, ISO-standards, and many more. 

Nasdaq BWise sales, service and support offices around the globe provide for the GRC needs of hundreds of leading companies worldwide. For more information, visit www.bwise.com.

About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,600 listed companies with a market value of approximately $9.6 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

- NDAQG-

         For Media Inquiries:
         Ryan Wells
         Email: ryan.wells@nasdaq.com
         Direct: +44 (0) 20 3753 2231
         Mobile: +44 (0) 7809 596 390

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 201817.7.2018 22:30Pressemelding

LYON, France and CAMBRIDGE, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018. At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including: - Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2017 and quietus of directors; - Allocation of the financial year's results; - Approval of regulatory agreements and commitments referred to in Article L.225-38 of the French Commercial Code; - Approval of the regulations of the share subscription and/or purchase options plan adopted by the Board of Directors on June 27, 2017; - Authorization for the Board of Directors to grant share subscription and/or share purchase options and/or to issue detachable share subscription warrants to corporate officers and employees of the Company or companies in the ERYTECH Pharma

Williams Scotsman Receives Competition Bureau Clearance for ModSpace Acquisition17.7.2018 22:15Pressemelding

BALTIMORE, July 17, 2018 (GLOBE NEWSWIRE) -- WillScot Corporation (NASDAQ:WSC) ("Williams Scotsman"), a specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that, on July 16, 2018, the Canadian Competition Bureau issued a No Action Letter relating to Williams Scotsman's proposed acquisition of Modular Space Corporation ("ModSpace"). WillScot has now obtained the regulatory approvals required to complete the acquisition and continues to progress towards closing in the third quarter of 2018. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the Williams Scotsman family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol "WSC." Williams Scotsman is a specialty rental services market leader providing innovative modular space and portable storage solutio

Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors17.7.2018 22:05Pressemelding

WALTHAM, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of Jeryl Hilleman to the Board of Directors of the Company. "Jeri brings a broad life sciences background to Minerva that includes high growth commercial biopharma, med-tech and data science companies," said William F. Doyle, Lead Independent Director of Minerva. "Her track record of delivering strategic and financial growth through execution, strategic partnering and multiple acquisitions will serve Minerva well as the Company completes five ongoing late-stage clinical trials with roluperidone, seltorexant and MIN-117." Ms. Hilleman is presently Chief Financial Officer of Intersect ENT (NASDAQ:XENT), a medical device company with commercial products for the treatment of chronic sinusitis. Previously, she served as CFO of several public

Orion Biotechnology Awarded a $2M Grant from National Center for Research and Development to Fund Further Development of its HIV Microbicide17.7.2018 21:00Pressemelding

OTTAWA, July 17, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that its European subsidiary, Orion Biotechnology Polska Sp. z o.o., was awarded a grant of $2M US dollars by the National Center for Research and Development . The grant will fund a project to advance development of the company's innovative microbicide candidate (OB-002H). Designed to prevent the transmission of HIV, OB-002H has the potential to address an urgent and growing need for an HIV prevention product that is affordable, appealing to use, and easily integrates into the lifestyles of people at risk for HIV infection regardless of age, sex or gender. The project is co-financed by the National Center for Research and Development under the InnoNeuroPharm program - Measure 1.2: Sectoral R & D programs of the Intelligent Development Operational Program 2014-2020. Orion Biotechnology will use the grant to complete IND enabling studies, advance OB-002H to

Greater Anglia Selects PowerPlan to Optimise Its Asset Investments17.7.2018 15:29Pressemelding

ATLANTA, July 17, 2018 (GLOBE NEWSWIRE) -- Greater Anglia, a UK-based train operating company, has selected PowerPlan's Asset Investment Optimization software suite to maximise its asset investments over a 40-year time period. Greater Anglia's long-term investment strategy includes a 40-year asset plan to meet its regulatory requirements. For what was historically built with manual processes and not easily tracked, the Asset Investment Optimization solution from PowerPlan will provide a comprehensive, auditable approach to help the company analyze different investment scenarios for impacts to risk, cost, timing and level of service and provide a defendable asset plan for the next four decades. "The condition of our assets drives our business," said Richard Turner, Head of Asset Management for Greater Anglia. "With PowerPlan, we can apply a fact-based methodology to prioritise investments, maximise their return and produce plans that communicate our asset strategy to internal and extern

Oxford Immunotec Schedules Second Quarter 2018 Earnings Release and Conference Call for July 31, 201817.7.2018 14:30Pressemelding

OXFORD, United Kingdom and MARLBOROUGH, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2018 financial results prior to market open on Tuesday, July 31, 2018. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 9268558, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom